Parkinson Disease

FDA approves Parcopa orally dissolving tablets for Parkinson disease

Published in Medical Letter on the CDC and FDA, October 3rd, 2004

SCHWARZ PHARMA, INC., announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Parcopa (carbidopa-levodopa orally disintegrating tablets), a unique formulation of carbidopa-levodopa that dissolves rapidly on the tongue.

Parcopa, which is available in pharmacies, is designed to provide patients suffering from Parkinson disease improved access to their medication.

Parkinson's disease patients experience symptoms such as morning rigidity or "off periods" - episodes of decreased movement or complete immobility during the day - that can make dosing problematic. Unlike conventional carbidopa-levodopa tablets,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-10-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry